Adverse Biological Responses to Drug-Impregnated Bioabsorbable Orthopedic Screws During Implant Degradation

Author Name : Hidoc internal team

Orthopedics

Page Navigation

Abstract

Drug-impregnated bioabsorbable orthopedic screws are designed to provide temporary mechanical fixation while gradually degrading and releasing a therapeutic agent at the surgical site. Their potential advantages include reduced long-term implant burden, lower need for hardware removal, and localized antimicrobial or osteogenic activity. However, degradation is biologically active rather than inert and may produce acidic or particulate by-products, local inflammatory reactions, fluid collections, delayed bone remodeling, and, in susceptible patients, infection-like or foreign-body presentations. The biological response depends on polymer composition, crystallinity, molecular weight, degradation kinetics, drug identity, implant geometry, host immune status, fixation demands, and local tissue environment. This review summarizes the disease burden, mechanisms, risk factors, clinical manifestations, diagnostic approach, management principles, emerging strategies, and guideline-based considerations relevant to adverse responses during degradation. Careful patient selection, accurate placement, surveillance, and multidisciplinary assessment are essential to distinguish expected resorption from clinically significant complications.

Introduction

Bioabsorbable orthopedic screws are used in selected procedures involving ligament reconstruction, osteochondral repair, fracture fixation, and other interventions requiring temporary stabilization. Common materials include poly-lactic acid, poly-glycolic acid, poly-lactide-co-glycolide, and related copolymers. Some devices incorporate antibiotics, anti-inflammatory agents, or osteoconductive compounds intended to improve local healing and reduce infection risk. Unlike permanent metallic implants, these devices undergo hydrolysis, fragmentation, cellular processing, and eventual clearance. The process can be clinically silent, but it may also provoke adverse biological responses that become apparent months or years after implantation.

Clinical interpretation is complicated because pain, swelling, radiolucency, cyst formation, and drainage may reflect normal remodeling, mechanical failure, sterile inflammation, or infection. In addition, evidence is heterogeneous because implant formulations, drug-release profiles, anatomical sites, surgical indications, and follow-up intervals vary considerably among studies. Healthcare professionals should therefore interpret device-specific safety data alongside clinical findings, imaging, microbiology, and the patient’s expected healing trajectory.

Epidemiology / Disease Burden

The frequency of adverse reactions varies widely by implant design and procedure. Many patients experience uncomplicated degradation, whereas others develop local inflammatory masses, osteolytic cavities, recurrent effusions, delayed incorporation, or fixation loss. Reported rates are difficult to compare because studies use different definitions for adverse events and may not distinguish mechanical complications from biological reactions. Events may be underrecognized when symptoms are attributed to recurrent injury or postoperative degeneration.

The burden is clinically important even when the reaction is sterile. Patients may require repeated imaging, aspiration, debridement, revision fixation, prolonged antimicrobial treatment, or delayed rehabilitation. A suspected implant-associated infection can lead to substantial functional impairment and healthcare utilization. In sports medicine and fracture care, late swelling or pain can interrupt return to activity and obscure assessment of graft or bone healing. The problem is particularly relevant for implants intended to remain in close proximity to synovium, articular cartilage, tendon-bone interfaces, or poorly vascularized bone.

Pathophysiology

Degradation generally begins with water penetration into the polymer matrix, followed by hydrolytic cleavage of ester bonds. Molecular weight declines before substantial loss of macroscopic integrity occurs. As degradation accelerates, acidic oligomers and particulate fragments may accumulate locally, especially when diffusion is limited. The resulting decrease in pH can irritate tissues, alter protein behavior, affect osteoblast and osteoclast activity, and intensify macrophage recruitment. Macrophages and foreign-body giant cells attempt to phagocytose fragments, releasing cytokines and chemokines that sustain inflammation.

Drug release adds another biological variable. An antimicrobial may produce local concentrations that are beneficial initially but decline unpredictably as the carrier changes structure. Burst release can cause transient cytotoxicity or tissue irritation, while incomplete release may provide inadequate protection against established biofilm. Drug crystallization, altered diffusion, and interactions between the active compound and polymer can change the intended pharmacokinetic profile. If the agent affects osteogenesis, angiogenesis, or local immune signaling, the healing response may be modified in either direction.

Mechanical and biological processes are interconnected. Progressive loss of screw strength may occur before complete resorption, increasing micromotion at the bone-implant interface. Micromotion can generate additional particles, delay osseous integration, and create a cycle of inflammation and structural instability. Intra-articular placement or migration may damage cartilage and provoke synovitis. Conversely, excessive fibrous encapsulation may isolate the implant from surrounding bone and contribute to delayed clearance.

Risk Factors

Important risk factors include large implant volume, high local polymer burden, rapid-degrading formulations, inadequate vascularity, poorly controlled diabetes, smoking, obesity, immunosuppression, malnutrition, and previous infection. Surgical contamination, dead space, insufficient irrigation, inappropriate tunnel or screw diameter, and excessive insertion torque may increase the probability of complications. Procedures in synovial or weight-bearing environments require particular attention because fluid movement, mechanical loading, and limited soft-tissue coverage can influence degradation and fixation.

Patient-specific susceptibility also matters. A history of exaggerated foreign-body reactions, autoimmune disease, atopy, metabolic bone disease, or impaired renal and hepatic function may complicate inflammatory or drug-related responses. Concomitant corticosteroid use and medications that influence bone turnover may delay incorporation. Risk assessment should include the expected need for high initial fixation strength, the feasibility of alternative implants, and the patient’s ability to attend follow-up and report delayed symptoms.

Clinical Features

Symptoms may appear early because of surgical trauma or later as degradation becomes active. Common manifestations include persistent or recurrent pain, localized swelling, warmth, restricted motion, joint effusion, tenderness over the implant, and reduced function. A sterile foreign-body reaction may present as a gradually enlarging mass, cyst, draining sinus without positive cultures, or radiolucent lesion near the screw. Mechanical failure can cause instability, loss of alignment, graft laxity, or recurrent fracture symptoms.

Infection must remain a central consideration. Fever and marked systemic illness may be absent in low-grade implant-associated infection. Increasing pain, erythema, drainage, elevated inflammatory markers, or a new fluid collection warrants structured evaluation rather than assumption of sterile inflammation. Neurological or vascular symptoms suggest migration, compression, or anatomic extension and require urgent assessment.

Diagnosis

Diagnosis begins with a detailed timeline linking symptoms to implantation, healing, and anticipated degradation. Examination should document wound status, joint stability, range of motion, neurovascular findings, and signs of mechanical failure. Laboratory testing may include complete blood count, C-reactive protein, and erythrocyte sedimentation rate, although normal results do not exclude indolent infection. When aspiration is feasible, synovial fluid cell count, differential analysis, Gram staining, aerobic and anaerobic cultures, and selected molecular or prolonged culture methods may be appropriate.

Plain radiographs can demonstrate tunnel widening, osteolysis, migration, alignment changes, or fracture. Magnetic resonance imaging may identify synovitis, fluid collections, marrow edema, graft integrity, and soft-tissue masses, although polymer-related artifacts and nonspecific inflammation can limit interpretation. Computed tomography is useful for defining cortical defects, cystic change, implant position, and union. Ultrasound may assist with superficial collections and image-guided aspiration. Tissue obtained during revision should be submitted for multiple cultures and histopathological examination to identify foreign-body giant cells, necrosis, acute inflammation, or chronic infection.

Treatment & Management

Management depends on symptoms, stability, infection probability, healing status, and the anatomical consequences of the reaction. Mild, stable, and clearly improving symptoms may be managed with observation, activity modification, analgesia, and serial clinical and radiographic review. Anti-inflammatory treatment can be considered selectively after infection and structural failure have been reasonably excluded. Rehabilitation should protect fixation while preserving safe mobility and function.

Persistent pain, enlarging collections, progressive osteolysis, migration, instability, or diagnostic uncertainty may require aspiration, biopsy, or surgical exploration. If infection is confirmed or strongly suspected, treatment should follow established principles of source control, appropriate tissue sampling, organism-directed antimicrobial therapy, and stabilization of the involved structure. Debridement or implant removal may be necessary when the implant is no longer mechanically required or when a persistent foreign-body reaction prevents healing. Bone defects may require grafting or other reconstructive techniques, and revision fixation should be selected according to the remaining bone quality and biological environment.

Recent Advances / Emerging Therapies

Current research focuses on polymers with more predictable mass loss, neutral or less acidic degradation products, improved mechanical retention, and controlled drug release. Composite systems incorporating bioactive ceramics, buffering compounds, or osteoconductive phases are being investigated to moderate local acidity and support bone formation. Surface engineering and microstructural control may reduce particle generation and improve tissue integration. Advanced manufacturing techniques are also being explored to tailor porosity, drug distribution, and degradation to a specific anatomical site.

Emerging approaches include responsive release systems that deliver antimicrobial agents in response to infection-associated conditions, combination therapies targeting both biofilm and inflammation, and imaging or biomarker strategies designed to distinguish sterile degradation from infection. These technologies remain subject to long-term evaluation. Demonstration of short-term antimicrobial activity is insufficient; clinically meaningful development requires evidence of mechanical reliability, biocompatibility, predictable resorption, functional outcomes, and safety across diverse patient populations.

Guideline Recommendations

Professional guidance generally supports a risk-based approach rather than routine intervention for every radiographic change. Surgeons should use approved devices within their labeled indications, review material composition and drug-release characteristics, document informed consent regarding delayed reactions, and maintain follow-up through the expected period of degradation. A new or worsening symptom should prompt assessment for infection, mechanical failure, and sterile inflammation in parallel.

When infection is possible, principles from orthopedic implant infection guidance should be applied, including obtaining deep cultures before antibiotics when the patient is clinically stable, avoiding reliance on a single negative test, and coordinating decisions among orthopedic surgeons, infectious disease specialists, radiologists, and pathologists. Routine prophylactic systemic antibiotics beyond established perioperative indications are not justified solely because a screw is bioabsorbable or drug impregnated. Device surveillance should include accurate reporting of delayed adverse events and long-term functional outcomes to improve future guideline development.

Conclusion

Drug-impregnated bioabsorbable orthopedic screws can provide useful temporary fixation and localized pharmacological activity, but their degradation may generate complex mechanical, inflammatory, infectious, and metabolic consequences. Acidic products, particulate debris, altered drug exposure, micromotion, and host susceptibility interact to determine clinical outcome. Persistent pain, swelling, effusion, osteolysis, drainage, or loss of stability should never be dismissed as routine resorption. Diagnosis requires correlation of clinical findings, laboratory studies, imaging, microbiology, and histopathology when indicated. Careful implant selection, meticulous technique, structured surveillance, and timely multidisciplinary management are central to reducing morbidity while preserving the potential advantages of bioabsorbable technology.

Featured News
Featured Articles
Featured Events
Featured KOL Videos

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot